Robert Arch, OncoSec Medical CEO
April 4, 2023 07:08 AM EDT
R&D

On­coSec re­ports flop for IL-12/Keytru­da com­bo in what may be fi­nal blow

Amber Tong

A six-year tri­al test­ing the com­bi­na­tion of On­coSec Med­ical’s IL-12 ther­a­py with Mer­ck’s Keytru­da has end­ed in fail­ure.

The com­bo

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times